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The development of an effective HIV vaccine is still a major scientiﬁc challenge. HIV vaccine trials con-
ducted until now were not able to induce broad neutralizing antibodies or effective cell mediated
immune responses. More recently, CD4+ T cells have been shown to play an important role in viral control
and better disease prognosis. We have recently developed a DNA vaccine encoding 18 conserved multiple
HLA-DR-binding HIV-1 CD4 epitopes (HIVBr18), capable of eliciting broad CD4+ T cell responses in BALB/c
and in multiple HLA class II transgenic mice. Despite the advantages of DNA vaccines and a large number
of clinical trials, it has been a challenge to transfer the success of inducing potent immunity observed in
animal models to humans. Here, we sought to evaluate the potential use of bupivacaine, a local anes-
thetic, as an adjuvant for HIVBr18. We observed that the concomitant administration of the local anes-
thetic bupivacaine with the DNA vaccine HIVBr18 increased the magnitude of CD4+ and CD8+ T cell
responses and cytokine production without compromising their breadth. Furthermore, we demonstrate
that coadministration of bupivacaine also impacted the longevity of speciﬁc immune responses. Since
bupivacaine is used in clinical settings, we believe that this concept may contribute to overcome the lim-
ited immunogenicity of DNA vaccines in humans.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction antibodies failed to induce Nabs and also failed large-scale efﬁcacyHuman immunodeﬁciency virus type 1 (HIV-1) infection and
the incurable disease it causes, the acquired immunodeﬁciency
syndrome (AIDS), remains a major public health problem in ende-
mic countries. Despite the successful development of new antiret-
roviral drugs in the last years, there is still no vaccine available.
In recent years, several studies have aimed to develop new
strategies for an effective vaccine to prevent HIV infection. It is
widely accepted that an effective prophylactic vaccine against
HIV-1 should elicit neutralizing antibodies (Nabs) that, if present
at the time of transmission, could block HIV acquisition. However,
all vaccine candidates based on the induction of neutralizingphase III trials [1,2]. Therefore, the HIV prophylactic vaccine
research shifted to evaluate vaccine candidates capable of inducing
cell-mediated immune responses (CMI). A vaccine that elicits CMI
will be able to limit viral transmission and prevent HIV-1 associ-
ated disease progression by controlling viral loads in those individ-
uals who become infected [3–5].
Although ﬁve vaccine candidates were tested in phase IIb/III
efﬁcacy trials, only one demonstrated some level of protection
[6]. The recent phase III clinical trial RV144 was the ﬁrst to demon-
strate a modest evidence of protection against acquisition of HIV-1
infection among vaccines in the absence of serum-neutralizing
antibodies, with an estimated vaccine efﬁcacy of 31.2% [7,8]. Preli-
minary analysis of the protective immune responses revealed that
most vaccinated HIV-negative individuals presented predomi-
nantly polyfunctional effector CD4+ T cell responses against the
V2 region of the envelope protein [9].
Control of viral infections is crucially dependent on CD4+ T cell
responses [10]. In this scenario, CD4+ T cells are mainly implicated
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porting B cells through antibody class switch recombination and
afﬁnity maturation. During HIV infection, and also in simian
immunodeﬁciency virus (SIV) infection in nonhuman primates,
CD4+ T cells can suppress virus replication directly (through the
release of perforin and granzymes) or indirectly (through the
release of soluble antiviral chemokines), maintain mucosal immu-
nity by producing IL-17, and produce cytokines to help B and CD8+ T
cells (for a review see [11]). In SIV infection, speciﬁc CD4+ T cells can
contribute directly to effective suppression of the virus by inhibiting
SIV replication in macrophages [12]. More recently, it was demon-
strated that HIV-infected individuals with lower set point viral load,
slower disease progression and better clinical outcome in the
absence of antiretroviral therapy, display signiﬁcant expansion of
HIV-speciﬁc CD4+ T cell responses.Moreover, these subjects present
enhanced CD4+ T cell cytolytic activity and higher frequency of IFN-
c producing cells [13]. It is thus clear that a successful HIV vaccine
should also induce strong CD4+ T cell responses [14].
We have identiﬁed a group of conserved CD4 epitopes from HIV
that were able to bind to multiple HLA-DR molecules. Synthetic
peptides representing such epitopes were recognized by PBMC
from over 90% of HIV-1 infected individuals [15]. More recently,
we reported that a DNA vaccine and a recombinant adenovirus
encoding such epitopes (HIVBr18) were able to induce broad
speciﬁc CD4+ and CD8+ T cell responses in BALB/c [16,17] and in
transgenic mice to human HLA class II alleles (HLA-DR2, -DR4,
-DQ6, -DQ8) [18]. Functional proﬁle analysis induced by these vac-
cines demonstrated that HIVBr18 was able to induce high magni-
tude, broad and polyfunctional CD4+/CD8+ T cell responses, and 8
out of 18 vaccine-encoded peptides were recognized. Moreover,
the vaccine also generated long-lived central and effector memory
T cells [16].
Immunization using plasmid DNA is a promising technology for
gene delivery. It offers several potential advantages over conven-
tional approaches, including safety proﬁle and feasible production
method [19]. Despite the advantages and a large number of clinical
trials, it has been a challenge to transfer the success of inducing
potent immunity observed in animal models to humans. The
mechanism of such phenomenon is not fully understood, but it is
likely that inefﬁcient transfection is a major determinant [20]. Such
observations have led to the pursuit of alternative strategies to
enhance immune responses to the encoding antigen [21]. One
alternative to improve the immunogenicity of DNA vaccines is
the concomitant use of adjuvants. Adjuvants (from the latin adjuv-
are = help) are substances that when incorporated into a vaccine
formulation, enhance its immunogenicity. Addition of such adju-
vants increases breadth, magnitude and also skews the type of
the immune response [21]. They can also lead to a reduction of
the dose and/or number of immunizations for a given vaccine
[22–24] and even increase seroconversion rates in populations
with reduced responsiveness [25,26]. To increase the immunoge-
nicity of DNA immunization using HIV antigens, genes coding cyto-
kines [27–30] and also toll like receptors (TLRs) agonists [31,32]
have been used.
Chemical compounds have been also evaluated as adjuvants for
DNA vaccines [33]. One of such compounds is bupivacaine or mar-
caine, a local anesthetic drug belonging to the amino amide group
that blocks neuron transmission. Bupivacaine is a myotoxin that
when injected destroys myoﬁber cells leading to the clearance of
cell debris and proliferation of myoblasts [34]. In addition, the
recruitment of inﬂammatory cells to the site of bupivacaine injec-
tion may allow for transfection of immune cells [35]. Pretreatment
of muscle with 0.25–0.5% bupivacaine prior to DNA injection
increases gene expression by 30–50-fold, resulting in an enhance-
ment of the immune responses [34,36]. Also, the complex formed
with bupivacaine protects DNA from nuclease degradation, andintramuscular immunization with this formulation results in
higher immune responses against the encoded antigen [33,37].
Further in support of the adjuvant effect of bupivacaine, mucosal
immunization with a DNA vaccine encoding an HIV-1 envelope
protein was able to elicit vaginal immunoglobulins that speciﬁcally
bound to the HIV-1 envelope and neutralized HIV-1 infectivity
in vitro [38]. Recently, bupivacaine was used in combination with
a DNA vaccine encoding Streptococcus mutants antigens, and intra-
nasal or intramuscular immunization induced antibodies, IFN-c
production and signiﬁcant reduction in dental caries lesions [39].
In the present study, we analyzed the adjuvant properties of the
concomitant use of bupivacaine on the cellular immune response
against the epitopes encoded by the DNA vaccine HIVBr18. Our
data suggest that the administration of a DNA vaccine encoding
HIV CD4 T cell epitopes together with bupivacaine at the time of
immunization results in enhancement of the magnitude and lon-
gevity of antigen-speciﬁc cellular immune responses.
Material and methods
DNA vaccine
We previously designed a multiepitope construct containing the
mammalian codon optimized nucleotide sequences of the 18 HIV-1
CD4 epitopes described previously [15]: p17 (73–89), p24 (33–45),
p24 (131–150), p6 (32–46), pol (63–77), pol (136–150), pol (785–
799), gp41 (261–276), gp160 (19–31), gp160 (174–185), gp160
(188–201), gp160 (481–498), rev (11–27), vpr (58–72), vpr (65–
82), vif (144–158), vpu (6–20) and nef (180–194). The artiﬁcial gene
(EZBiolab) was cloned into the pVAX1 vector (Invitrogen) to gener-
ate the HIVBr18 vaccine, as previously described [16,18]. The DNA
vaccine was puriﬁed using the Endofree Plasmid Giga Kit from Qia-
gen according to manufacturer’s instructions.
Mice and immunization
BALB/c mice were purchased from Centro de Desenvolvimento
de Modelos Experimentais para Medicina e Biologia (CEDEME)
and housed at the experimental animal facilities at the Division
of Immunology, Federal University of São Paulo (UNIFESP) under
speciﬁc pathogen-free conditions. In all experiments, groups of 6
mice were immunized intramuscularly (IM) three times, 2 weeks
apart, with 100 lg of the DNA vaccine HIVBr18 in the presence
or absence of 0.2% bupivacaine hydrochloride (Sigma). Control
mice received 100 lg of the empty vector pVAX in the presence
or absence of 0.25% bupivacaine hydrochloride. A volume of
50 lL was injected into each quadriceps.
Ethics statement
All experiments were performed in accordance to the guidelines
of the Ethics committee of Federal University of São Paulo (UNI-
FESP) and approved under protocol number 0121/11.
Peptide synthesis
The eighteenmultipleHLA-DRbindingpeptides derived from the
conserved regions of HIV-1 B subtype consensus were synthesized
byGLBiochem(Vancouver, Canada). Peptidepurityandqualitywere
assessedby reverse-phasehighperformance liquidchromatography
and mass spectrometry and were routinely above 90%.
Spleen cells isolation
Two or twelve weeks after the last dose, mice were euthanized
and the spleen was removed aseptically. After obtaining single cell
suspensions, cells were washed in 10 mL of RPMI 1640. Cells were
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bovine serum (gibco), 2 mM L-glutamine (gibco), 1 mM sodium
piruvate (gibco), 1% vol/vol vitamine solution (gibco), 1% v/v non-
essential aminoacids solution (gibco), 40 lg/mL of Gentamicin,
20 lg/mL of Peﬂacin and 5  105 M 2-mercaptoetanol (Sigma).
Cell viability was evaluated using 0.2% Trypan Blue exclusion dye
to discriminate between live and dead cells. Cell concentration
was estimated with the aid of a cell counter (Countess-Invitrogen)
and adjusted in cell culture medium.
Enzyme-linked immunospot assays (ELIspot)
Splenocytes from immunized mice were assayed for their abil-
ity to secrete IFNc or IL-2 after in vitro stimulation with 5 lM of
individual or pooled HIV-1 peptides using ELISPOT assay. The ELI-
SPOT assay was performed using murine IFN-c or IL-2 ELISPOT kit
(BD Biosciences) according to manufacturer’s instructions. Spots
were counted using an automated stereomicroscope (KS ELISPOT,
Zeiss). The cutoff was 15 SFU per million splenocytes.
Cytometric bead array
One million splenocytes were incubated for 120 h at 37 C in
the presence of 5 lM pooled HIV-1 peptides. Supernatants har-
vested from cultures were stored at 20 C until cytokine analysis.
IL-2, IL-4, IL-5, TNFa and IFN-c were detected simultaneously
using mouse Th1/Th2 Cytokine cytometric bead array (CBA) Kit
(BD Biosciences), according to manufacturer’s instructions. The
range of detection was 20–5000 pg/mL for each cytokine.
CFSE-based proliferation assay
To monitor the expansion and proliferation of HIV-speciﬁc T
cells, splenocytes from immunized mice were labeled with car-
boxyﬂuorescein succinimidyl ester (CFSE) [40]. Brieﬂy, freshly iso-
lated splenocytes were resuspended (50x106/mL) in PBS and
labeled with 1.25 lM of CFSE (Molecular Probes) at 37 C for
10 min. The reaction was quenched with RPMI 1640 supplemented
with 10% FBS (R10) and cells were washed before resuspending in
R10. Cells were cultured in 96 well round-bottomed plates
(5  105/well in triplicate) for 5 days at 37 C and 5% CO2 with
medium only or pooled HIV-1 peptides (5 lM). Cells were then
harvested, washed with 100 lL of FACS buffer (PBS with 0.5%
BSA and 2 mM EDTA) and stained with anti-CD3 PE, anti-CD4
PerCP and anti-CD8 APC monoclonal antibodies (BD Pharmingen)
for 45 min at 4 C. Cells were then washed and resuspended in
FACS buffer. Samples were acquired on a FACSCanto ﬂow cytome-
ter (BD Biosciences) and then analyzed using FlowJo software (ver-
sion 10, Tree Star).
Analysis of polyfunctional HIV-speciﬁc T cell responses
CFSE-labeled cells were incubated at a density of 2.5  106
cells/mL and cultured in 96 well round-bottomed plates (5  105/
well in triplicate) for 4 days at 37 C and 5% CO2 with medium only
or pooled HIV peptides (5 lM). After 4 days of incubation, cells
were restimulated in the presence of 2 mg/mL anti-CD28 (BD
Pharmingen), 5 lM of pooled HIV peptides and Brefeldin A-
GolgiPlug™ (BD Pharmingen) for the last 12 h. After the incubation
period, cells were washed with FACS buffer and surface stained
using monoclonal antibodies to CD8-Paciﬁc Blue and CD4-PerCP
for 30 min at 4 C. Cells were ﬁxed and permeabilized using the
Cytoﬁx/Cytoperm™ kit (BD Pharmingen). Permeabilized cells were
washed with Perm/Wash buffer (BD Biosciences) and stained with
monoclonal antibodies to CD3-APCCy7, IL2-PE, TNFa-PECY7 and
IFNc-APC for 30 min at 4 C. Following staining, cells were washedtwice and resuspended in FACS buffer. All antibodies were from BD
Pharmingen. Samples (1,000,000 events in a live lymphocyte gate)
were acquired on a FACSCanto ﬂow cytometer (BD Biosciences)
and then analyzed using FlowJo software (version 9.0.2, Tree Star,
San Carlo, CA). The percentages of proliferating-cytokine producing
cells were calculated by subtracting background values. For each
ﬂow cytometry experiment performed in this paper, unstained
and all single-color controls were processed to allow proper
compensation.
Data analysis
Statistical signiﬁcance (p-values) was calculated by using One-
way ANOVA and Tukey’s honestly signiﬁcantly different (HSD) or
unpaired t test. Statistical analysis and graphical representation of
data were performed using GraphPad Prism version 5.0 software.
Results
Bupivacaine enhances the magnitude of T cell responses
To analyze whether immunization in the presence of bupiva-
caine could enhance vaccine-speciﬁc T cell responses, mice were
immunized with the DNA vaccine HIVBr18 in the presence or
absence of the anesthetic. Control mice were immunized with
the empty vector pVAX with or without bupivacaine. Fifteen days
after the last dose, splenocytes from immunized mice were iso-
lated and cultured with pooled HIV-1 peptides and speciﬁc IFNc
and IL-2 secretion were measured by ELISPOT assay. We observed
a signiﬁcantly higher number of peptide-speciﬁc IFNc secreting
cells in spleen from mice immunized in the presence of bupiva-
caine (Fig. 1A), and the same phenomenon was observed for IL-2
production (Fig. 1B). In contrast, splenocytes from pVAX1 immu-
nized mice presented negligible numbers of cytokine secreting
cells to the same HIV-1 peptides.
To discriminate between the effect of bupivacaine in vaccine-
speciﬁc CD4+ and CD8+ speciﬁc T cell responses, we performed a
CFSE-dilution proliferation assay. Taking into account multiple
experiments, we observed that addition of bupivacaine was able
to increase CD4+ and CD8+ T cell proliferation (Fig. 2A and B,
respectively).
In order to analyze thevaccine inducedcytokine secretionproﬁle,
splenocytes from immunized mice were cultured with pooled HIV
peptides and the assessment of Th1 and Th2 cytokines was deter-
mined by ﬂow cytometry using cytometric bead array (CBA). After
culture,wedetected secretionof TNFa, IFN-c and IL-2 andnegligible
levels of IL-5 and IL-4 in splenocytes derived frommice immunized
with HIVBr18 in the presence or absence of bupivacaine (Fig. 3).
Interestingly, we observed a higher production of these cytokines
in culture of splenocytes from mice immunized with bupivacaine.
In contrast, splenocytes from pVAX1 immunized mice failed to
secrete the same cytokines against the same peptides.
Using multiparameter ﬂow cytometry, we sought to character-
ize antigen-speciﬁc T cells (CD4+ and CD8+) based on their ability
to proliferate (CFSE dilution assay) and produce the cytokines
IFN-c, TNFa and IL-2 at a single cell level. Using boolean platform
analysis, that allows the identiﬁcation of proliferating cells that
produce any cytokine in any combination, we found that bupiva-
caine acts as an adjuvant increasing the numbers of proliferating
CD4+ and CD8+ T cells that produce the effector cytokines
(Fig. 4A and B, respectively). In fact, we detected as many as 8.5%
and 14% of proliferating (CFSElow)-cytokine producing CD4+ and
CD8+ T cells, respectively.
Splenocytes from pVAX1 immunized mice presented negligible
levels of proliferation and cytokine secreting cells against the same
HIV-1 pooled peptides.
Fig. 1. Immunization with HIVBr18 and bupivacaine induces higher number of IFN-
c and IL-2 secreting cells against HIV peptides. Two weeks after the last
immunization with HIVBr18 in the presence or absence of bupivacaine, spleen
cells from 6 BALB/c mice per group were cultured in the presence of pooled HIV-1
peptides (5 lM) or medium only. Frequencies of HIV peptide-speciﬁc IFN-c (A) and
IL-2 (B) secreting cells were measured by ELISPOT assay. These data are represen-
tative of four independent immunization experiments with similar results; SFU:
spot forming units; ⁄⁄⁄p < 0.001. Data represent mean ± SD.
Fig. 2. Coadministration of HIVBr18 and bupivacaine enhances speciﬁc T cell
proliferation. Proliferative T cell responses were assessed by CFSE dilution assay.
Splenocytes from immunized mice were labeled with CFSE and cultured for 5 days
in the presence of pooled HIV-1 peptides or medium only. After staining with
ﬂuorochrome-labeled anti-CD3, -CD4 and -CD8 monoclonal antibodies, cells were
analyzed by ﬂow cytometry. CFSE dilution on gated CD3+CD4+ (A) or CD3+CD8+ (B)
cells was used as a read out for antigen-speciﬁc proliferation. Five hundred
thousand events were acquired in a live lymphocyte gate. The percent of
proliferating CD4+ and CD8+ CFSElow cells was determined in the CD3+ cell
population. The percentage of proliferating T cells was calculated subtracting the
values of peptide-stimulated from non-stimulated cultures. Data are representative
of four independent immunization experiments with similar results; ⁄⁄⁄p < 0.001.
Data represent mean ± SD.
Fig. 3. Immunization with HIVBr18 together with bupivacaine induces higher Th1
type cytokine production. Two weeks after the last immunization, pooled spleen
cells from 6 BALB/c mice per group were cultured in the presence of 5 lM of pooled
HIV-1 peptides or medium only. After 120 h, levels of IFN-c, TNFa, IL-2, IL-4 and IL-
5 in culture supernatants were measured using the mouse Th1/Th2 cytokine
cytometric bead array (CBA) by ﬂow cytometry, and analyzed using FCAP array
software. Values of cytokine production by peptide-stimulated splenocytes from
pVAX immunized group were always below the detection limit. Data are
representative of four independent immunization experiments with similar results.
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the overall magnitude of the Th1 vaccine induced immune
responses.Bupivacaine does not alter the breadth of T cell responses
Given that immunization with bupivacaine increased the over-
all magnitude of speciﬁc cellular immune responses, we asked
whether such an effect would affect the breadth of speciﬁc
response. For this purpose, we determined the number of IFN-cand IL-2 secreting cells against each vaccine-encoded peptide indi-
vidually. Noteworthy, immunization with HIVBr18 induced
responses against the same 8 out of 18 vaccine encoded peptides
that were previously described by our group [16]. Peptides p17
(73–89), p6 (32–46), pol (63–77), gp160 (188–201), rev (11–27),
vpr (65–82), vif (144–158) and nef (180–194) were able to induce
both IFN-c and IL-2 secreting cells and we observed no signiﬁcant
impact on the breadth of speciﬁc immune response irrespective
the use of bupivacaine as an adjuvant (Fig. 5A and B). The use of
bupivacaine had an impact on the magnitude of IFN-c and IL-2
responses for the peptides p17 (73–89), p6 (32–46), pol (63–77),
gp160 (188–201), rev (11–27) and vpr (65–82). These results dem-
onstrate that bupivacaine plays a role in the magnitude but not in
the breadth of the vaccine-speciﬁc immune response.
Long-lived T cell responses after immunization with bupivacaine
A critical feature of an effective vaccine adjuvant is its ability to
promote long-term immunological memory. To address whether
bupivacaine could improve memory induction in immunized mice,
we measured vaccine-induced cytokine production and T cell pro-
liferation. Ninety days after the last dose we detected a statistically
signiﬁcant decrease in the magnitude of IFNc production, CD4+ and
CD8+ T cell proliferative responses when compared to an early time
point (15 days). Also, we observed that mice immunized with HIV-
Br18 plus bupivacaine presented slightly higher numbers of IFN-c
secreting cells when compared to mice immunized with HIVBr18
only (Fig. 6A). Interestingly, we found that 8% of CD4+ and 17% of
CD8+ T cells from mice immunized in the presence of bupivacaine
retained proliferative capacity against HIV-1 peptides 90 days after
the last dose (Fig. 6B and C, respectively). In contrast, 4.8% of CD4+
and 12% of CD8+ T cells from mice immunized with HIBr18 alone
proliferated against HIV peptides. Splenic T cells from pVAX immu-
nized mice showed negligible levels of proliferation and numbers
of IFN-c secreting cells. Thus, these results demonstrate that
bupivacaine also facilitates the development of vaccine-induced
memory responses.Discussion
In the present study we sought to evaluate the concomitant use
of bupivacaine to improve the immunopotency of an HIV DNA vac-
cine. The DNA vaccine used in this work, HIVBr18, encodes 18 CD4+
T cell promiscuous HIV-1 epitopes that were previously described
Fig. 4. Immunization with HIVBr18 together with bupivacaine induces proliferating T cells with a polyfunctional type 1 cytokine proﬁle. Two weeks after the last
immunization, spleen cells from 6 mice per group were collected, labeled with CFSE and cultured for 4 days in the presence of pooled HIV-1 peptides or medium only. On day
4, cells were pulsed for 12 h with pooled peptides in the presence of costimulatory antibody and Brefeldin A. Cells were then surface stained with antibodies to CD4 and CD8,
permeabilized and stained for intracellular cytokines (IFN-c, TNFa and IL-2) and CD3. Total frequencies of proliferating (CFSElow) and cytokine-producing CD4+ (A) and CD8+
(B) T cells were determined by Boolean combination analysis. Background responses detected in negative control tubes were subtracted from those detected in stimulated
samples for every speciﬁc functional combination. Negative control tubes include cells stimulated with medium and cells from pVAX1 immunized mice stimulated with
pooled peptides. For each sample, 106 events were collected in the live lymphocyte gate; ⁄p < 0.05. Data are representative of four independent immunization experiments
with similar results. Data represent mean ± SD.
Fig. 5. Immunization with HIVBr18 and bupivacaine induces IFN-c and IL-2 secretion and proliferation against multiple HIV-1 epitopes. Two weeks after the last
immunization with HIVBr18 or the empty pVAX1 vector, pooled spleen cells from 6 BALB/c mice per group were cultured in the presence of individual HIV-1 peptides or
medium only. Frequencies of HIV peptide-speciﬁc IFN-c (A) and IL-2 (B) secreting cells were measured by ELISPOT assay; SFU: spot forming units; Data are representative of
four independent immunization experiments with similar results. Data represent mean ± SD.
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infected individuals [15]. We also demonstrated that this vaccine
induced polyfunctional, long-lasting and broad immune responses
in several strains of mice, including transgenic to human HLA class
II molecules [16,18].
To our knowledge this study is the ﬁrst to characterize the effect
of the concomitant use of Bupivacaine with a DNA vaccine encod-
ing several epitopes on vaccine-speciﬁc cellular immune
responses. Bupivacaine is usually administered several days before
immunization with the vaccine [36], but such delay in conjunction
with the fact that the injection must be at the same site poses a
major concern when large-scale vaccination is needed. Recently,
bupivacaine mixed with DNA generated a similar immune
response when compared to separated administration [41].
We demonstrated that immunization of mice with the DNA vac-
cine in the presence of bupivacaine was able to increase the mag-
nitude of vaccine-speciﬁc cellular immune responses. The
production of type 1 cytokines, proliferation of CD4+ and CD8+ Tcells and induction of polyfunctional T cells was higher in the
group coimmunized with HIVBr18 and bupivacaine. Bupivacaine
has been used before as an adjuvant for a DNA vaccine encoding
the envelope protein of HIV to enhance antibody titers and neutral-
ization ability [38].
The development of a vaccine against HIV that induces cellular
mediated immune responses by speciﬁc CD4+ and CD8+ T cells in
order to confer long-term protective immunity is supported by
several studies [4,5]. It is believed that this type of vaccine would
reduce viral load and transmission and postpone the development
of the onset of the disease-related symptoms [42]. Strong speciﬁc
CD4+ T cell response is associated with control of viral replication
and long-term nonprogression to AIDS [11,43–45]. Furthermore,
CD4+ T cells from HIV-infected patients have been shown to
express large amounts of cytolytic effector molecules, and HIV-
speciﬁc CD4+ T cell clones and cell lines can readily mediate target
cell lysis and viral inhibition in vitro [12,13,46], even in the
absence of genetic and immunological environment that favors
Fig. 6. Coadministration of HIVBr18 and bupivacaine enhances longevity of antigen speciﬁc cellular immune responses. BALB/c mice immunized with HIVBr18 were
euthanized 90 days after the last immunization. Pooled spleen cells from 6 BALB/c mice per group were cultured in the presence of individual HIV-1 peptides or medium only.
(A) Frequencies of IFNc secreting cells as measured by ELISPOT assay. (B) Percentage of proliferating CD3+CD4+ and CD3+CD8+ T cells ⁄p < 0.05; NS non signiﬁcant. Data are
representative of four independent immunization experiments with similar results. Data represent mean ± SD.
100 S.P. Ribeiro et al. / Trials in Vaccinology 3 (2014) 95–101the generation of protective HIV-speciﬁc responses [47]. Polyfunc-
tional HIV-1-speciﬁc CD4+ T cells are normally present among
HIV-1 infected individuals with nonprogressive disease [48,49].
Moreover, HIV elite controllers present strong polyfunctional
CD4+ and CD8+ T cell responses in blood and rectal mucosa [50,51].
Memory T cells may be critical to generate long-term immunity
and to effectively induce vaccine viral control. For example, immu-
nization with the effective vaccinia virus is able to generate speciﬁc
long-lived memory CD4+ T cells that survive for more than 30 years
[52]. Notably, we previously demonstrated that HIVBr18 immuni-
zation induced a long-lived memory cell pool [53]. We hereby
demonstrated that co-immunization with bupivacaine also
induced long-lasting memory responses against vaccine encoded
HIV-1 peptides with higher magnitude than HIVBr18 alone.We believe that the data provided here may contribute for the
development of a future HIV DNA-based vaccine.
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